Summary:
The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive decline compared with placebo treatment, as measured by a composite cognitive measure, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants who are asymptomatic at risk for developing Alzheimer's dementia.
Qualified Participants Must:
• Between the ages of 60-85
•
Not having memory loss
• Availability of a study partner.
Qualified Participants May Receive:
May be compensated for time and travel.